Abstract: Immunogenic compositions and systems are disclosed, as well as methods for producing the immunogenic compositions. Compositions, systems, and methods of reducing viability of cancer cells and treating cancer, as well as methods of reducing volume of a tumor and/or preventing an increase in volume of a tumor present in a body of a living subject, are also disclosed. The systems and methods involve application of an alternating electric field to cancer cell(s) (before or after isolation from a targeted portion of a subject), and irradiation of the isolated and treated cancer cell(s). The methods may further include administration of the irradiated, treated cancer cells back to the subject from which the cancer cell(s) were isolated, and/or application of an alternating electric field to the subject. The immunogenic compositions comprise populations of isolated, apoptotic cancer cells.

Abstract: Compositions, systems, and methods for activating dendritic cells are disclosed. Also disclosed are compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase in volume of a tumor present in a body of a living subject, along with methods of treating other diseases and infections. The systems and methods involve application of an alternating electric field to dendritic cell(s) in vivo or ex vivo and/or to a subject or cancer cells isolated therefrom. The systems and methods may further include administration of activated dendritic cells to a subject. The compositions comprise populations of isolated dendritic cells activated by exposure to an alternating electric field.

Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.

Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.

Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.

Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.